{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:57:05Z","timestamp":1720486625031},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ejim.2017.12.010","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T06:07:19Z","timestamp":1514354839000},"page":"6-11","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Resistant hypertension: Renal denervation or intensified medical treatment?"],"prefix":"10.1016","volume":"50","author":[{"given":"Alberto","family":"Morganti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2017.12.010_bb0005","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension","volume":"125","author":"Dougherty","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2017.12.010_bb0010","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2017.12.010_bb0015","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","article-title":"Prevalence of resistant hypertension in the United States, 2003\u20132008","volume":"57","author":"Persell","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0020","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring","volume":"57","author":"de la Sierra","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)70151-3","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.12.010_bb0030","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.amjhyper.2005.05.014","article-title":"Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension","volume":"18","author":"Pierdomenico","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0035","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2015.142","article-title":"Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension","volume":"88","author":"Sim","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2017.12.010_bb0040","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1111\/j.1523-1755.2005.09906.x","article-title":"Chronic renal failure: a cardiovascular risk factor","volume":"99","author":"Fort","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.ejim.2017.12.010_bb0045","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study","volume":"373","author":"Krum","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.12.010_bb0050","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.110.163014","article-title":"Catheter-based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months","volume":"57","author":"Symplicity HTN-1 Investigators","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0055","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1161\/CIRCULATIONAHA.112.130880","article-title":"Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug resistant hypertension: one year results from the Symplicity HTN-2 randomized, controlled trial","volume":"126","author":"Esler","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2017.12.010_bb0060","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"SYMPLICITY HTN-3. A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2017.12.010_bb0065","first-page":"R245","article-title":"Translational medicine: the antihypertensive effect of renal denervation","volume":"298","author":"Di Bona","year":"2010","journal-title":"Am J Phys Regul Integr Comp Phys"},{"key":"10.1016\/j.ejim.2017.12.010_bb0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tcm.2014.09.014","article-title":"Renal denervation for treatment of drug-resistant hypertension","volume":"25","author":"Esler","year":"2015","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.ejim.2017.12.010_bb0075","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ijcard.2014.09.138","article-title":"Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension","volume":"177","author":"Grassi","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2017.12.010_bb0080","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/HYPERTENSIONAHA.115.05449","article-title":"Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure","volume":"66","author":"Dudenbostel","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/01.HYP.11.1.3","article-title":"Assessment of Human Sympathetic Nervous System activity from measurements of norepinephrine turnover","volume":"11","author":"Esler","year":"1988","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0090","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/00004872-198910000-00008","article-title":"Effect of angiotensin converting enzyme inhibition on cardiovascular regulation during reflex sympathetic activation in sodium-replete patients with essential hypertension","volume":"7","author":"Morganti","year":"1989","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0095","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/01.CIR.96.1.148","article-title":"Intracoronary angiotensin II potentiates coronary sympathetic vasoconstriction in humans","volume":"96","author":"Saino","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2017.12.010_bb0100","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1152\/physrev.1991.71.3.659","article-title":"Functional role of renal afferents","volume":"71","author":"Stella","year":"1991","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ejim.2017.12.010_bb0105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/jama.1946.02870080001001","article-title":"The surgical treatment of essential hypertension","volume":"130","author":"Peet","year":"1946","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2017.12.010_bb0110","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/jama.1953.03690160001001","article-title":"Splanchnicectomy for essential hypertension; results in 1266 cases","volume":"152","author":"Smithwick","year":"1953","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2017.12.010_bb0115","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1093\/eurheartj\/eht197","article-title":"Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial","volume":"34","author":"Malaiapan","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2017.12.010_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"SPYRAL HTN-OFF MED trial investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial","author":"Townsend","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.12.010_bb0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4244\/EIJV8I1A10","article-title":"First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension","volume":"8","author":"Mabin","year":"2012","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ejim.2017.12.010_bb0130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.carrev.2015.04.008","article-title":"Next generation renal denervation: chemical \u201cperivascular\u201d renal denervation with alcohol using a novel drug infusion catheter","volume":"16","author":"Fischell","year":"2015","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.ejim.2017.12.010_bb0135","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jacc.2011.11.034","article-title":"Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension","volume":"59","author":"Brandt","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2017.12.010_bb0140","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.jacc.2012.08.959","article-title":"Effects of renal denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension","volume":"60","author":"Brandt","year":"2012","journal-title":"JACC"},{"key":"10.1016\/j.ejim.2017.12.010_bb0145","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/HYPERTENSIONAHA.113.01728","article-title":"Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea","volume":"62","author":"Linz","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0150","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/HYPERTENSIONAHA.112.193870","article-title":"Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension","volume":"60","author":"Mahfoud","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0155","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1161\/HYPERTENSIONAHA.111.173799","article-title":"Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea","volume":"58","author":"Witkowski","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0160","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1586\/erc.13.52","article-title":"Renal denervation in treatment-resistant hypertension: the need for restraint and more and better evidence","volume":"11","author":"Persu","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ejim.2017.12.010_bb0165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurheartj\/ehu441","article-title":"Predictors of blood pressure response in the Symplicity HTN-3 trial","volume":"36","author":"Kandzari","year":"2015","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.ejim.2017.12.010_bb0170","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.03.059","article-title":"Anatomic assessment of sympathetic peri-arterial renal nerves in man","volume":"64","author":"Sakakura","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2017.12.010_bb0175","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/ajh\/hpu258","article-title":"Catether-based radiofrequency renal denervation: location effects on renal norepinephrine","volume":"28","author":"Henegar","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0180","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(14)61942-5","article-title":"Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial","volume":"385","author":"Azizi","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.12.010_bb0185","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1161\/HYPERTENSIONAHA.114.04823","article-title":"Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects","volume":"65","author":"Grassi","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0190","series-title":"Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension","first-page":"263","article-title":"European Network Coordinating Research On Renal Denervation (ENCOReD) Consortium","volume":"24","author":"Fadl Elmula","year":"2015"},{"key":"10.1016\/j.ejim.2017.12.010_bb0195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/jhh.2013.88","article-title":"European Network Coordinating research on Renal Denervation (ENCOReD). Blood pressure changes after renal denervation at 10 European expert centers","volume":"28","author":"Persu","year":"2014","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0200","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jacc.2013.06.023","article-title":"Renal denervation in moderate treatment-resistant hypertension","volume":"62","author":"Ott","year":"2013","journal-title":"Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2017.12.010_bb0205","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1097\/HJH.0000000000001085","article-title":"Global SYMPLICITY Registry Investigators. Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension: 12-month outcomes from the global SYMPLICITY registry","volume":"34","author":"B\u00f6hm","year":"2016","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0210","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1097\/HJH.0000000000000751","article-title":"Blood pressure variability after catheter-based renal sympathetic denervation in patients with resistant hypertension","volume":"33","author":"Ewen","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0215","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/HYPERTENSIONAHA.112.201186","article-title":"Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients. Prospective Case Series","volume":"60","author":"Brinkmann","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0220","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/HYPERTENSIONAHA.114.04336","article-title":"Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension","volume":"65","author":"Ewen","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0225","first-page":"93","article-title":"Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry","volume":"38","author":"Mahfoud","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2017.12.010_bb0230","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/HYPERTENSIONAHA.111.00095","article-title":"Blood pressure and autonomic responses to electrical stimulation of the renal arterial nerves before and after ablation of the renal artery","volume":"61","author":"Chinusci","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0235","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.amjcard.2015.02.055","article-title":"Frequency of renal artery stenosis after renal denervation in patients with resistant arterial hypertension","volume":"115","author":"Lambert","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2017.12.010_bb0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11906-016-0676-z","article-title":"Renal afferents","volume":"18","author":"Frame","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ejim.2017.12.010_bb0245","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1161\/01.HYP.0000157368.09939.88","article-title":"Arterial stiffening influence of sympathetic nerve activity: evidence from hand transplantation in humans","volume":"45","author":"Giannattasio","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0250","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/HJH.0000000000000841","article-title":"Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes","volume":"34","author":"Hirakawa","year":"2016","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0255","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11906-017-0728-z","article-title":"Preferred fourth-line pharmacotherapy for resistant hypertension: are we there yet?","volume":"19","author":"Prosser","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ejim.2017.12.010_bb0260","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldostronism as a common case of resistant hypertension","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ejim.2017.12.010_bb0265","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/HJH.0b013e3282a9be30","article-title":"Aldosterone excess and resistance to 24-h blood pressure control","volume":"25","author":"Pimenta","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0270","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/HYPERTENSIONAHA.116.08632","article-title":"Distinctive risk factors and phenotype of younger patients with resistant hypertension","volume":"69","author":"Ghazi","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0275","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2017.12.010_bb0280","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","article-title":"Low-renin status in therapy-resistant hypertension: a clue to efficient treatment","volume":"22","author":"Eide","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0285","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.ejim.2017.12.010_bb0290","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","article-title":"Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study","volume":"30","author":"Bobrie","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0295","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.HYP.0000116223.97436.e5","article-title":"Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy","volume":"43","author":"Goodfriend","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0300","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","article-title":"Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008","volume":"124","author":"Egan","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2017.12.010_bb0305","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","article-title":"Plasma aldosterone is independently associated with the metabolic syndrome","volume":"48","author":"Bochud","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0310","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.amjhyper.2004.05.017","article-title":"Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled","volume":"17","author":"Bramlage","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0315","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1161\/HYPERTENSIONAHA.116.07806","article-title":"Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension","volume":"68","author":"Dudenbostel","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0320","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1210\/jc.2008-0251","article-title":"Primary Aldosteronism Prevalence in Hypertension Study Investigators. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients","volume":"93","author":"Rossi","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2017.12.010_bb0325","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/j.1550-8528.1999.tb00418.x","article-title":"Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women","volume":"7","author":"Goodfriend","year":"1999","journal-title":"Obes Res"},{"key":"10.1016\/j.ejim.2017.12.010_bb0330","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","article-title":"Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis","volume":"132","author":"Huby","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2017.12.010_bb0335","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1749-6632.2012.06597.x","article-title":"Visceral adipose tissue: emerging role of gluco- and mineralocorticoid hormones in the setting of cardiometabolic alterations","volume":"1264","author":"Boscaro","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejim.2017.12.010_bb0340","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2017.12.010_bb0345","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fphys.2017.00369","article-title":"The effect of renal denervation on plasma adipokine profile in patients with treatment resistant hypertension","volume":"8","author":"Eikelis","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.ejim.2017.12.010_bb0350","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0355","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension","volume":"55","author":"de Souza","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0360","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","article-title":"Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial","volume":"31","author":"Oxlund","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0365","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","article-title":"The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies","volume":"28","author":"Dahal","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2017.12.010_bb0370","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial","volume":"57","author":"V\u00e1clav\u00edk","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0375","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.12.010_bb0380","first-page":"397","article-title":"Role of adding spironolactone and renal denervation in true resistant hypertension","volume":"65","author":"Rosa","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2017.12.010_bb0385","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.107.690396","article-title":"The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio","volume":"116","author":"Hood","year":"2007","journal-title":"Circulation"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517305095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517305095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T02:25:37Z","timestamp":1535163937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620517305095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":77,"alternative-id":["S0953620517305095"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2017.12.010","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistant hypertension: Renal denervation or intensified medical treatment?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2017.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}